



High-frequency percussive ventilation improves oxygenation and ventilation in pediatric patients with acute respiratory failure[☆]



Nicole A. Rizkalla, MD^a, Cheryl L. Dominick, RRT-NPS^b, Julie C. Fitzgerald, MD, PhD^a, Neal J. Thomas, MD, MSc^c, Nadir Yehya, MD^{a,*}

^a Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA

^b Department of Respiratory Care, The Children's Hospital of Philadelphia, Philadelphia, PA

^c Department of Pediatrics and Public Health Science, Division of Pediatric Critical Care Medicine, Penn State Hershey Children's Hospital, Hershey, PA

ARTICLE INFO

Keywords:

High-frequency ventilation
High-frequency percussive ventilation
Acute respiratory failure
Acute respiratory distress syndrome
Acute lung injury

ABSTRACT

Purpose: High-frequency percussive ventilation (HFPV) in pediatrics has been described predominantly in burned patients. We aimed to describe its effectiveness and safety in noninhalational pediatric acute respiratory failure (ARF).

Methods: We conducted an observational study in a tertiary care pediatric intensive care unit on 31 patients with ARF failing conventional ventilation transitioned to HFPV. Demographics, ventilator settings, oxygenation index, oxygen saturation index, oxygen saturation as measured by pulse oximetry/fraction of inspired oxygen (FIO₂), and PaO₂/FIO₂ were recorded before and during HFPV.

Results: Initiation of HFPV was associated with improvements in oxygenation index, oxygen saturation index, PaO₂/FIO₂, and oxygen saturation as measured by pulse oximetry/FIO₂ as early as 12 hours ($P < .05$), which continued through 48 hours after transition. Improved oxygenation occurred without an increase in mean airway pressures. Reductions in PaCO₂ occurred 6 hours after initiation of HFPV and continued through 48 hours ($P < .01$). Improved gas exchange was accompanied by reduced peak-inflating pressures at all time intervals after initiation of HFPV ($P < .01$). Vasopressor scores were similar before and after initiation of HFPV in patients requiring vasoactive support. Twenty-six (83.9%) of 31 patients survived to hospital discharge.

Conclusions: In a heterogeneous population of pediatric ARF failing conventional ventilation, HFPV efficiently improves gas exchange in a lung-protective manner.

© 2014 Elsevier Inc. All rights reserved.

1. Introduction

Acute respiratory failure (ARF) is a leading cause of morbidity and mortality in pediatric intensive care units (PICUs), and mechanical ventilation remains the mainstay of therapy. Ventilator-induced lung injury has been a well-documented consequence of mechanical ventilation [1,2], prompting use of lung-protective strategies and the development of alternative nonconventional modes of ventilation [1–5].

High-frequency percussive ventilation (HFPV) is a unique mode that attempts to combine the beneficial effects of conventional and high-frequency ventilation [6]. It stacks successive subtidal volume breaths at a rapid rate superimposed upon conventional cyclic rates, allowing for progressive stepwise inflation of the lung to a set peak pressure, and a passive exhalation to a predetermined lower pressure.

Continuous pneumatic compressions also allow for a mobilization of retained airway secretions [7].

High-frequency percussive ventilation was initially described in burned patients with inhalational injury, where it efficiently mobilized retained soot compared with conventional ventilation [8–10]. More recently, HFPV has been described in adult patients without burn injury but with ARF, primarily as a rescue mode for patients unable to meet oxygenation and ventilation goals with conventional ventilation [11–14]. High-frequency percussive ventilation is consistently reported to improve oxygenation at lower pressures than those used for conventional ventilation, despite a lack of reduction of mortality or ventilator days [11,14,15].

In pediatric burned patients [9,10,16–18], retrospective studies have also suggested lower inflation pressures and improved oxygenation. A prospective trial comparing conventional ventilation with HFPV in burned children demonstrated lower inflation pressures and marginally improved oxygenation with HFPV, but showed no significant outcome differences [16]. The single published report of HFPV use in nonburn pediatric ARF was as a salvage mode in an infant with hydrocarbon aspiration [19]. Despite use of this mode of ventilation for more than 3 decades, the use and efficacy of HFPV as

[☆] Conflicts of interest: We declare that we have no conflicts of interest. Financial support: Russell C. Raphaely, Endowed Chair in Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia.

* Corresponding author. Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, Suite 7C-26, 34th St and Civic Center Blvd, Philadelphia, PA 19104. Tel.: +1 215 590 7430; fax: +1 215 590 4327.

E-mail address: yehyan@email.chop.edu (N. Yehya).




Fig. 1. Time-pressure tracing of the HFPV ventilatory cycle on the VDR-4. The ventilator delivers pneumatically driven, subtidal volume breaths at a set percussive rate (shown as 500 breaths/min) successively to a high pressure (peak inspiratory pressure or, alternatively, the pulsatile flow rate) for a predetermined inspiratory time. Exhalation to a preset low pressure (end-expiratory pressure analogous to positive end-expiratory pressure) is passive and kept there for a preset expiratory time. Reproduced with permission from Percussionaire.

a primary ventilator strategy or rescue mode in nonburn pediatric respiratory failure is unknown.

In this study, we describe our initial experiences with HFPV in pediatric patients with ARF. We aimed to evaluate the changes in respiratory and hemodynamic function in patients with ARF in whom HFPV was initiated after failure of conventional ventilation. We hypothesized that there would be a significant and sustained improvement in oxygenation and a reduction in peak-inflating pressures after transition from conventional ventilation to HFPV.

2. Methods

2.1. Patient selection and design

We conducted a retrospective observational study in patients receiving HFPV for failure of conventional ventilation at the Children's Hospital of Philadelphia, a 55-bed, tertiary care PICU. All patients were identified from a database of HFPV use. The study was approved by the hospital institutional review board, and the requirement for informed consent was waived. All consecutive patients receiving HFPV between October 1, 2010, and January 31, 2012, were eligible for inclusion, which totaled 40 patients. Patients were excluded if HFPV was initiated for reasons other than failure of conventional ventilation, which removed 9 patients from our consecutive cohort: in 4 patients, HFPV was empirically initiated for smoke inhalation; in another 4 patients, HFPV was used during extracorporeal membrane oxygenation; and in 1 patient, a diagnosis of unrepaired cardiac disease prompted transfer out of our PICU. This left 31 patients available for analysis.

2.2. Conventional ventilation strategy

Determination of failure of conventional ventilation and decision to use alternate modes were left to the discretion of the attending physician. Despite the lack of a formal protocol, our institutional practice for respiratory failure is to initiate conventional ventilation with a minimum of 5 cm H₂O of end-expiratory pressure and 6 to 8 mL/kg of tidal volume and to attempt to wean fraction of inspired oxygen (F_{IO₂}) to 0.60 or less. Inability to wean F_{IO₂} prompts escalation of end-expiratory pressures and subsequent repeat efforts to wean F_{IO₂}, with the goal to maintain peak inspiratory pressures of 32 cm H₂O or less. Persistently elevated peak pressures (≥ 32 cm H₂O), ongoing hypercarbia (Paco₂ ≥ 80 or pH < 7.30), or oxygenation difficulties (inability to wean F_{IO₂} ≤ 0.60 despite increasing end-expiratory pressure) prompt reevaluation of the ventilatory strategy and a change in the mode of ventilation. All patients were ventilated with a decelerating flow waveform on conventional ventilation, justifying our use of peak-inflating pressures as a risk factor for alveolar distension.

2.3. High-frequency percussive ventilation strategy

Our institution uses the VDR-4 (Percussionaire, Sandpoint, Idaho). Typical HFPV starting settings used were a high-frequency percussive rate of 500 to 600 breaths/min (lower rates for hypercarbia)

Table 1
Characteristics of patient population and HFPV use

Variable ^a	(n = 31)
Age (y)	1.6 (0.6, 6.8)
Weight (kg)	10.0 (7.1, 25.2)
Sex (male), n (%)	15 (48.4)
Race, n (%)	
Asian/Pacific Islander	1 (3.2)
Black/African American	10 (32.2)
Hispanic	3 (9.7)
White	17 (54.8)
PRISM III at 12 h	6.5 (1, 11)
Immunocompromised, n (%)	6 (19.4)
Length of mechanical ventilation before transition to HFPV (d)	1.0 (0.0, 4.0)
Vasopressors, n (%)	18 (58.1)
Vasopressor score ^b before transition to HFPV (n = 18)	5.0 (2.0, 12.0)
Vasopressor score after transition to HFPV (n = 18)	7.5 (5.0, 14.0)
Ancillary therapy used before HFPV ^c , n (%)	
Neuromuscular blockade	16 (51.6)
Inhaled nitric oxide	9 (29.0)
HFOV	3 (9.7)
Corticosteroids	5 (16.1)
Prone positioning	2 (6.5)
Exogenous surfactant	1 (3.2)
Severity of oxygenation impairment, n (%)	
PF ratio < 200 (n = 16 ^d)	15 (93.8)
SF ratio < 264 ^e (n = 31)	25 (80.6)
SF ratio < 221 ^e (n = 31)	19 (61.3)
Barotrauma, n (%)	
Before transition to HFPV	3 (9.7)
After transition to HFPV	4 (12.1)
Reason for stopping HFPV, n (%)	
Significant improvement in respiratory failure	23 (74.2)
Death or withdrawal of life support	5 (16.1)
Inadequate improvement, dyssynchrony, or poor tolerance	3 (9.7)
Total HFPV days	4.0 (2.3, 6.0)
Total ventilator days	16.0 (10.0, 22.8)
Total PICU length of stay (d)	22.0 (17.0, 34.8)
Mortality, n (%)	5 (16.1)

^a Continuous data are in the form of median (25th, 75th percentiles), and categorical data are in the form of n (%).

^b Vasopressor score = dopamine dose ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 1 + dobutamine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 1 + epinephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + norepinephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + phenylephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + milrinone ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 10. Vasopressor score medians (interquartile range) reflect only the 18 patients ever exposed to these medications.

^c More than 1 category was possible.

^d Arterial blood gas data available for 16 patients.

^e Cutoff values for mild and moderate/severe ARDS using noninvasive, SpO₂-based measures of oxygenation impairment.

superimposed on a convective rate of 10 to 30 breaths/min, a peak pressure matching that used on the conventional ventilator, an inspiratory/expiratory ratio of 1:1, and an end-expiratory pressure equal to or slightly above the pressure used on conventional (Fig. 1). Adjustments are made on the basis of invasive and noninvasive measurements of oxygenation and ventilation, including pulse oximetry and transcutaneous CO₂ monitoring, with preferential reduction in peak pressures with improving ventilation and reductions in FiO₂ until at least 0.60 for improving oxygenation. Pressures are measured at the proximal endotracheal tube; specifically, a pressure manometer connected to the inhalational limb of the circuit adjacent to the proximal endotracheal tube is attached to the VDR-4 and continuously displays measured pressures on the ventilator.

2.4. Data collection

Medical records of patients were reviewed for diagnoses, demographics, the severity of illness Pediatric Risk of Mortality (PRISM) III score at 12 hours of PICU admission, preexisting conditions, indication for mechanical ventilation, length of PICU stay, length of mechanical ventilation, and discharge status. We recorded ventilator settings, vasopressor score, presence of pneumothorax or pneumomediastinum, blood gas measurements, and the use of adjunctive therapies (inhaled nitric oxide, surfactant, methylprednisolone, neuromuscular blockade, and prone positioning) before and after (at 6, 12, 24, and 48 hours) initiation of HFPV.

2.5. Equations

We used a modification of a previously described vasopressor score [20–22]: dopamine dose ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 1 + dobutamine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 1 + epinephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + norepinephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + phenylephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + milrinone ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 10. Measures of oxygenation recorded in the study were the PaO₂/FiO₂ (PF ratio) and the oxygenation index (OI), calculated as the (mean airway pressure [mPaw] \times FiO₂ \times 100/PaO₂). In addition, we report the oxygen saturation as measured by pulse oximetry (SpO₂)/FiO₂ (SF ratio) and the oxygen saturation index (OSI; [mPaw \times FiO₂ \times 100]/SpO₂), metrics to describe oxygenation in children with ARF with less readily available arterial access [23–25] that have been associated with mortality [26]. Owing to the nonlinear relationship between PaO₂ and SpO₂ at higher SpO₂ values, patient data were only used when SpO₂ is at least 97%.

2.6. Statistical analysis

Continuous data are reported as mean (\pm SEM) or median (25th, 75th percentiles) for normally and nonnormally distributed variables, respectively. Categorical data are reported as frequencies and percentages. Paired or unpaired parametric and nonparametric comparisons of continuous variables were performed as appropriate. Categorical variables were compared using the Fisher exact test.

Table 2

Gas exchange, ventilator settings, hemodynamics, and other therapies at initiation of, and after transition to, HFPV among patients failing conventional mechanical ventilation (n = 31)

Variable ^a	Conventional ventilation before transition to HFPV (0 h)	HFPV hour 24	p ^b
Ventilator settings			
Peak inspiratory pressure	38.0 (29.5, 41.3)	26.0 (24.0, 33.0)	<.001
End-expiratory pressure	10 (8.5, 12)	10 (8, 12)	.683
Tidal volume (mL/kg)	7.0 (6.2, 7.8)	–	–
Mean airway pressure	18.0 (13.3, 21.5)	17.0 (14.5, 19.3)	.640
Superimposed percussive rate	–	600 (500, 600)	–
Gas exchange			
OI ^c (n = 16)	18.7 (\pm 2.2)	12.0 (\pm 2.2)	.040
PF ratio ^c (n = 16)	131.5 (\pm 17.5)	187.4 (\pm 13.2)	.020
OSI (n = 31)	9.8 (6.8, 14.1)	6.0 (4.8, 9.3)	<.001
SF ratio (n = 31)	182.9 (127.1, 230.9)	250.0 (215.3, 323.5)	<.001
PaCO ₂ ^c (n = 16)	84.1 (\pm 11.7)	57.8 (\pm 10.2)	<.001
PvCO ₂ ^d (n = 15)	61.6 (\pm 7.2)	43.3 (\pm 9.7)	.022
Ancillary therapy			
Neuromuscular blockade	16 (51.6%)	17 (54.8%)	1.0
Inhaled nitric oxide (iNO)	9 (29.0%)	14 (45.2%)	.29
Gas exchange in patients started on iNO during transition to HFPV			
OI ^c (n = 3)	21.6 (21.2, 25.4)	9.8 (6.4, 18)	.250
PF ratio ^c (n = 3)	92.6 (73.7, 108.9)	204.1 (134.3, 220.8)	.250
OSI (n = 5)	19.2 (9.5, 20.4)	9.6 (5, 11.4)	.125
SF ratio (n = 5)	125.0 (95.7, 170.6)	244.9 (192.2, 294.5)	.063
PaCO ₂ ^c (n = 3)	48.7 (45.5, 79.5)	53.7 (42, 57.6)	.500
Gas exchange in patients not started on iNO during transition to HFPV			
OI ^c (n = 13)	15.4 (12.5, 26.9)	9.3 (8.2, 11.8)	.063
PF ratio ^c (n = 13)	134.2 (76.4, 187.1)	195.7 (165.3, 209.2)	.077
OSI (n = 26)	8.3 (5.9, 13.8)	5.9 (4.4, 8.6)	.002
SF ratio (n = 26)	186.6 (141.8, 231.9)	250.0 (221.9, 324.8)	<.001
PaCO ₂ ^c (n = 13)	77.7 (67.1, 95.5)	48.0 (41.6, 55.5)	<.001
Vasopressor use			
Vasopressor score ^e	14 (45.2%)	16 (51.6%)	
	5.0 (2.0, 12.0)	7.5 (5.0, 14.0)	.200
Barotrauma	3 (9.7%)	4 (12.1%)	1.0

PvCO₂, partial pressure of carbon dioxide in mixed venous blood.

^a Continuous data are in the form of mean (\pm SEM) or median (25th, 75th percentiles), and categorical data are in the form of n (%).

^b Means are compared using a paired *t* test, and medians are compared using with a Wilcoxon signed rank test for paired data. Categorical variables are compared using a Fisher exact test.

^c Arterial blood gas data available for 16 patients.

^d Venous blood gas data available for determination of Pvco₂ (partial pressure of carbon dioxide in mixed venous blood) in the 15 patients without arterial access.

^e Vasopressor score = dopamine dose ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 1 + dobutamine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 1 + epinephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + norepinephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + phenylephrine ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 100 + milrinone ($\mu\text{g kg}^{-1} \text{min}^{-1}$) \times 10. Vasopressor score medians [interquartile range] reflect only the 18 patients ever exposed to these medications.

Comparison of normally distributed variables over time was conducted using a repeat-measure analysis of variance (ANOVA) and post hoc Tukey. Comparisons of nonnormally distributed variables over time were made using a 1-way Friedman rank sum procedure and a paired nonparametric statistic for repeat measures, followed by 2-tailed Wilcoxon matched-pairs test with a Bonferroni correction. All tests compared variables at 6, 12, 24, and 48 hours of HFPV to pretransition (0 hours) values. Significance is defined as $P < .05$ for all analyses after correction for multiple testing. Calculations were performed in SigmaPlot 11.0 (Systat Software Inc, San Jose, Calif).

3. Results

3.1. Patient characteristics and illness severity before initiation of HFPV

Thirty-one patients with ARF who failed conventional mechanical ventilation were treated with HFPV during the 15-month study period (48.4% male), with a median age of 1.6 (0.6, 6.8) years (Table 1). Three patients (9.7%) were managed with high-frequency oscillatory ventilation (HFOV) before initiation of HFPV. Fifteen patients (48%) transitioned from pressure-controlled conventional ventilation, with the remaining 16 patients transitioning from pressure-regulated volume control using a decelerating waveform. The etiology of lung injury in our population (Supplementary Table 1) was predominantly respiratory infection (67.7%). Bacterial and viral pneumonia comprised most of diagnoses (58%). Secondary lung injury from infectious complications occurred in 2 patients, one from *Klebsiella* bacteremia with septic shock and a second from septic emboli from Lemierre disease. Before initiation of HFPV, 6 of 31 patients met the suggested noninvasive oxygenation criteria [24] for mild (SF ratio < 264), and 19 of 31 met the suggested criteria for moderate/severe (SF ratio < 221) acute

respiratory distress syndrome (ARDS). Of the 16 patients with arterial catheters and available PaO₂ data, 15 had a PF ratio less than 200, suggesting more severe lung disease in this subgroup. The median duration of conventional ventilation before transition to HFPV was 1 (0, 4) day. Adjunctive respiratory treatments used before HFPV initiation are detailed in Table 1, with the most common being continuous neuromuscular blockade (51.6%) and inhaled nitric oxide (29.0%).

Median PRISM III score was 6.5 (1, 11), and 6 patients (19.4%) were immunocompromised, reflecting a moderately ill pediatric population. Preexisting comorbid conditions are detailed in Supplementary Table 1. Six patients (19.4%) had underlying chronic lung disease defined by chronic oxygen requirement. One patient had a preexisting tracheostomy without ventilator dependence. No patients had baseline invasive mechanical ventilator support requirements. Four patients (12.9%) had previous organ or stem cell transplantation. Vasopressors were used in 18 (58.1%) patients, with similar vasopressor scores before and after transition to HFPV ($P = .20$ Wilcoxon signed rank test).

3.2. Clinical outcomes

Patients received a median of 4 (2.3, 6) days of HFPV and were ventilated for a median of 16 (10, 22.8) days. The observed frequency of barotrauma as defined by new pneumomediastinum or pneumothorax was not significantly different before and after transition to HFPV ($P = 1.0$, Fisher exact test). Overall mortality was 5 (16.1%) of 31 patients, which represented 5 of the 6 immunocompromised patients. In 3 patients, persistent inadequate oxygenation or patient-ventilator dyssynchrony refractory to neuromuscular blockade led to discontinuation of HFPV (Table 1). One of these patients was transitioned to HFOV, and 2 patients were transitioned to extracorporeal support.




Fig. 2. Changes in OI (A), OSI (B), PF ratio (C), and SF ratio (D) after 48 hours of HFPV in patients failing conventional mechanical ventilation ($n = 31$; 16 patients had arterial blood gas data available). The first measurement represents values of these variables just before initiation of HFPV (0 hours). Measurements are taken at 6, 12, 24, and 48 hours after HFPV initiation. Oxygenation index and PF ratio are normally distributed (mean \pm SEM, $n = 16$), and comparison over time was conducted using a repeated-measure ANOVA and a post hoc Tukey honestly significant difference (HSD). Oxygen saturation index and SF ratio are not normally distributed (median and interquartile range, $n = 31$), and comparison of these variables over time was made using a one-way Friedman rank sum procedure and a paired nonparametric statistic, followed by 2-tailed Wilcoxon matched-pairs test with a Bonferroni correction. All tests compared variables at 6, 12, 24, and 48 hours of HFPV to pretransition (0 hours) values. $*P < .05$; $**P < .01$ after correction for multiple testing. The number of patients still on HFPV at each time point is given below.

3.3. Respiratory outcomes

Gas exchange was evaluated before and after transition to HFPV. Sixteen of the 31 patients possessed arterial catheters (Table 2), allowing measurement of OI and PF ratios. For all 31 patients, OSI and SF ratios were used to assess response to HFPV. Peak inflating and mean airway pressures were compared for all patients before and after transition to HFPV.

Oxygenation and ventilation both significantly improved after initiation of HFPV. Oxygenation index decreased from a mean of 18.7 (± 2.2) to 11.7 (± 1.6) at 12 hours of HFPV and remained significantly lower than pre-HFPV levels throughout the 48 hours of measurement. This was paralleled by similar improvements in OSI, PF, and SF ratios (Table 2; Fig. 2). Oxygenation improvement was achieved without an increase in mean airway pressure (Table 2; Figure 3). Significant reduction of $Paco_2$ from a mean of 84.1 (± 11.7) to 55.1 (± 8.9) mm Hg was achieved by 6 hours after initiation of HFPV and remained significantly lower for 48 hours (Table 2; Fig. 4). Importantly, the peak-inflating pressures required to achieve ventilation were also significantly reduced at 6 hours after HFPV initiation from a median of 38 (29.5, 41.3) to 30 (26, 32) cm H₂O, with sustained reduction through 48 hours (Table 2; Fig. 3).

Improvements in oxygenation and ventilation on HFPV were not associated with a significant increase in the use of neuromuscular blockade or inhaled nitric oxide (Table 2). The 5 patients with initiation of inhaled nitric oxide concurrent with transition to HFPV were analyzed separately and showed substantial but statistically insignificant improvements in all oxygenation parameters (Table 2). The remaining 26 patients had significant improvements in OSI, SF ratio, and $Paco_2$ and insignificant improvements in OI and PF ratio (Table 2). High-frequency percussive ventilation initiation did not result in more air leaks, increased vasopressor requirement, or higher vasopressor scores (Table 2).

4. Discussion

The major finding of this study is the significant improvement in gas exchange with HFPV at lower peak-inflating pressures in pediatric patients with ARF caused by heterogeneous primary and secondary lung insults. Importantly, oxygenation improved without an increase in mean airway pressures. Lower peak pressure was achieved and sustained during the 48 hours after initiation of HFPV.

Although this mode of ventilation has been used in clinical practice for several decades, its reported use in pediatrics has been limited to patients with smoke inhalational injury [9,10,16–18]. Carman et al [16] studied 64 pediatric burned patients randomized to HFPV or conventional ventilation managed with a low-tidal volume strategy. High-frequency percussive ventilation improved oxygenation at lower peak-inflating pressures when compared with conventional. No significant differences were noted in other outcome measures, including sepsis, pneumonia, ARDS incidence, or mortality.

High-frequency percussive ventilation has been described in the adult population in scenarios ranging from polytrauma with ARDS to inhalational injuries. A recent prospective trial in adult burned patients randomized 62 patients to HFPV or conventional ventilation at admission [15]. The HFPV group demonstrated significantly improved oxygenation with lower peak-inflating pressures during the first 48 hours after initiation with no significant change in hemodynamics or clinically evident barotrauma. There were no differences in ventilator-free days or mortality. Cioffi et al [8] reported a series of 54 burned patients with inhalation injury placed on “prophylactic” HFPV within 1 hour of admission to the hospital, compared results in this population with historical controls, and found that the HFPV group had a significantly lower incidence of pneumonia and improved mortality.

Part of the reluctance to apply this mode to traditional ARDS may be due to the inability to accurately record delivered tidal volumes on

HFPV, a shortcoming shared by other modes of high-frequency ventilation, including high-frequency oscillation and high-frequency jet ventilation [27]. This raises the concern that dangerously high-tidal volumes may be delivered unmonitored, risking volutrauma and worse outcomes in this population. Despite this, HFPV has been studied as salvage therapy for adult ARF and ARDS refractory to other modes of ventilation [11–14,28,29]. In a prospective trial of 100 adults with ARF, patients were randomized to conventional mechanical ventilation or HFPV and treated to predefined respiratory parameters. Each group met predefined gas exchange end points; however, the subset of patients with ARDS treated with HFPV maintained significantly lower airway pressures when compared with the ARDS group managed with conventional ventilation. There were no reported differences between the 2 groups in mortality or hospital length of stay [30].

Limitations of this study are inherent to the single-center, retrospective nature of this report. Approaches to conventional ventilation and ventilator escalation were subject to the clinician's discretion before transition to HFPV. Respiratory adjuncts were used in differing order and for varied durations before initiation of HFPV. Strengths of this study include the heterogeneity of disease processes in this data set that accurately represents the pediatric patient population with ARF and the magnitude and consistency of the




Fig. 3. Changes in mean airway pressure (A) and peak-inflating pressure (B) after 48 hours of HFPV in patients failing conventional mechanical ventilation ($n = 31$). The first measurement represents values of these variables just before initiation of HFPV (0 hours). Measurements are taken at 6, 12, 24, and 48 hours after HFPV initiation. Values are expressed as median (25th, 75th percentiles), and comparison of these variables over time was made using a 1-way Friedman rank sum procedure and a paired nonparametric statistic, followed by 2-tailed Wilcoxon matched-pairs test with a Bonferroni correction. All tests compared variables at 6, 12, 24, and 48 hours of HFPV to pretransition (0 hours) values. $^{***}P < .01$ after correction for multiple testing. The number of patients still on HFPV at each time point is given below.




Fig. 4. Changes in PaCO₂ after 48 hours of HFPV in patients failing conventional mechanical ventilation (n = 16 patients with arterial blood gas data available). The first measurement represents PaCO₂ just before initiation of HFPV (0 hours). Measurements are taken at 6, 12, 24, and 48 hours after HFPV initiation. Values are expressed as mean (± SEM), and comparison over time was conducted using a repeated-measure ANOVA and a post hoc Tukey honestly significant difference (HSD). All tests compared variables at 6, 12, 24, and 48 hours of HFPV to pretransition (0 hours) values. **p < .01 after correction for multiple testing. The number of patients still on HFPV at each time point is given below.

response to HFPV. Patients had significant oxygenation defects before transition, and despite lack of a standardized ventilator escalation protocol, transition to HFPV occurred fairly early in patients' course while on escalating conventional ventilation settings. It is possible that these patients would have had improved gas exchange with reduced peak airway pressures had they remained on conventional ventilation. However, at the time of transition to HFPV, all were failing to meet oxygenation and ventilation goals with lung-protective settings on conventional ventilation, and it was this failure that prompted a transition to HFPV. The retrospective, noncontrolled nature of the study precludes firm conclusions regarding the benefits of HFPV leading to improved gas exchange at lower peak-inflating pressures but does support a future prospective investigation of HFPV vs other modes of nonconventional ventilation for pediatric ARF failing conventional. Finally, the use of noninvasive measures of oxygenation, such as SF ratio and OSI, allowed us to extract meaningful data from nearly twice the number of patients than reliance on arterial blood gas data alone would have allowed. This requirement for invasive arterial sampling has limited recruitment in several pediatric studies of ARF [23,31], and our study represents an example of reliable noninvasive markers based on pulse oximetry, thereby facilitating pediatric ARF research.

5. Conclusions

Use of HFPV results in a consistent and sustained improvement in oxygenation and ventilation at reduced peak-inflating pressure in pediatric ARF, achieving goals consistent with lung-protective ventilation. Oxygenation improved without increased mean airway pressure. Further prospective studies are needed to define the population that can be maximally benefited by HFPV, to identify the optimal time for initiation, and to better elucidate secondary benefits that may be gained by airway clearance.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.jcrc.2013.11.009>.

Acknowledgments

We thank Rita Giordano, RRT-NPS; Leah Rhodes, RRT; and Maureen Ginda, RRT-NPS, from our respiratory care department for

their clinical support. We thank Akira Nishisaki, MD, and Richard Lin, MD, for assistance with data collection.

References

- [1] Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med* 2000;342(18):1301–8.
- [2] Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998;338(6):347–54.
- [3] Fedora M, Klimovic M, Seda M, Dominik P, Nekvasil R. Effect of early intervention of high-frequency oscillatory ventilation on the outcome in pediatric acute respiratory distress syndrome. *Bratisl Lek Listy* 2000;101(1):8–13.
- [4] Habashi NM. Other approaches to open-lung ventilation: airway pressure release ventilation. *Crit Care Med* 2005;33(3 Suppl):S228–40.
- [5] Krishnan JA, Brower RG. High-frequency ventilation for acute lung injury and ARDS. *Chest* 2000;118(3):795–807.
- [6] Salim A, Martin M. High-frequency percussive ventilation. *Crit Care Med* 2005;33(3 Suppl):S241–5.
- [7] Hall JJ, Hunt JL, Arnoldo BD, Purdue GF. Use of high-frequency percussive ventilation in inhalation injuries. *J Burn Care Res* 2007;28(3):396–400.
- [8] Cioffi Jr WG, Rue III LW, Graves TA, McManus WF, Mason Jr AD, Pruitt Jr BA. Prophylactic use of high-frequency percussive ventilation in patients with inhalation injury. *Ann Surg* 1991;213(6):575–80 [discussion 580–572].
- [9] Cortiella J, Mlcak R, Herndon D. High frequency percussive ventilation in pediatric patients with inhalation injury. *J Burn Care Rehabil* 1999;20(3):232–5.
- [10] Rue III LW, Cioffi WG, Mason AD, McManus WF, Pruitt Jr BA. Improved survival of burned patients with inhalation injury. *Arch Surg* 1993;128(7):772–8 [discussion 778–780].
- [11] Salim A, Miller K, Dangleben D, Cipolle M, Pasquale M. High-frequency percussive ventilation: an alternative mode of ventilation for head-injured patients with adult respiratory distress syndrome. *J Trauma* 2004;57(3):542–6.
- [12] Velmahos GC, Chan LS, Tatevossian R, Cornwell III EE, Dougherty WR, Escudero J, et al. High-frequency percussive ventilation improves oxygenation in patients with ARDS. *Chest* 1999;116(2):440–6.
- [13] Paulsen SM, Killyon GW, Barillo DJ. High-frequency percussive ventilation as a salvage modality in adult respiratory distress syndrome: a preliminary study. *Am Surg* 2002;68(10):852–6 [discussion 856].
- [14] Hurst JM, Branson RD, Davis Jr K. High-frequency percussive ventilation in the management of elevated intracranial pressure. *J Trauma* 1988;28(9):1363–7.
- [15] Chung KK, Wolf SE, Renz EM, Allan PF, Aden JK, Merrill GA, et al. High-frequency percussive ventilation and low tidal volume ventilation in burns: a randomized controlled trial. *Crit Care Med* 2010;38(10):1970–7.
- [16] Carman B, Cahill T, Warden G, McCall J. A prospective, randomized comparison of the Volume Diffusive Respirator vs conventional ventilation for ventilation of burned children. *J Burn Care Rehabil* 2002;23(6):444–8 [2001 ABA paper].
- [17] Reper P, Dankaert R, van Hille F, van Laeke P, Duinslaeger L, Vanderkelen A. The usefulness of combined high-frequency percussive ventilation during acute respiratory failure after smoke inhalation. *Burns* 1998;24(1):34–8.
- [18] Reper P, Wibaux O, Van Laeke P, Vandeenen D, Duinslaeger L, Vanderkelen A. High frequency percussive ventilation and conventional ventilation after smoke inhalation: a randomised study. *Burns* 2002;28(5):503–8.
- [19] Mabe TG, Honeycutt T, Cairns BA, Kocis KC, Short KA. High-frequency percussive ventilation in a pediatric patient with hydrocarbon aspiration. *Pediatr Crit Care Med* 2007;8(4):383–5.
- [20] Wernovsky G, Wypij D, Jonas RA, Mayer Jr JE, Hanley FL, Hickey PR, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. *Circulation* 1995;92(8):2226–35.
- [21] Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. *Pediatr Crit Care Med* 2010;11(2):234–8.
- [22] den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF. One single dose of etomidate negatively influences adrenocortical performance for at least 24 h in children with meningococcal sepsis. *Intensive Care Med* 2008;34(1):163–8.
- [23] Khemani RG, Patel NR, Bart III RD, Newth CJ. Comparison of the pulse oximetric saturation/fraction of inspired oxygen ratio and the Pao₂/fraction of inspired oxygen ratio in children. *Chest* 2009;135(3):662–8.
- [24] Khemani RG, Thomas NJ, Venkatachalam V, Scimeme JP, Berutti T, Schneider JB, et al. Comparison of SpO₂ to Pao₂ based markers of lung disease severity for children with acute lung injury. *Crit Care Med* 2012;40(4):1309–16.
- [25] Thomas NJ, Shaffer ML, Willson DF, Shih MC, Curley MA. Defining acute lung disease in children with the oxygenation saturation index. *Pediatr Crit Care Med* 2010;11(1):12–7.
- [26] Ghuman AK, Newth CJ, Khemani RG. The association between the end tidal alveolar dead space fraction and mortality in pediatric acute hypoxemic respiratory failure. *Pediatr Crit Care Med* 2012;13(1):11–5.
- [27] Allan PF. High-frequency percussive ventilation: pneumotachograph validation and tidal volume analysis. *Respir Care* 2010;55(6):734–40.
- [28] Gallagher TJ, Boysen PG, Davidson DD, Miller JR, Leven SB. High-frequency percussive ventilation compared with conventional mechanical ventilation. *Crit Care Med* 1989;17(4):364–6.

- [29] Hurst JM, Branson RD, DeHaven CB. The role of high-frequency ventilation in post-traumatic respiratory insufficiency. *J Trauma* 1987;27(3):236–42.
- [30] Hurst JM, Branson RD, Davis Jr K, Barrette RR, Adams KS. Comparison of conventional mechanical ventilation and high-frequency ventilation. A prospective, randomized trial in patients with respiratory failure. *Ann Surg* 1990;211(4):486–91.
- [31] Khemani RG, Newth CJ. The design of future pediatric mechanical ventilation trials for acute lung injury. *Am J Respir Crit Care Med* 2010;182(12):1465–74.